Minerva Neurosciences Inc (NERV)

Trade NERV now with
8/25/2017 8:31:17 AM Minerva Neurosciences Reports European Commission Approval Of Amendment Of MIN-202 Agreement With Janssen
8/3/2017 7:49:31 AM Minerva Neurosciences Q2 Net Loss $9.8 Mln Or $0.27/shr Vs. Net Loss $5.2 Mln Or $0.18/shr Last Year
7/24/2017 8:32:40 AM Minerva Neurosciences: Michele Ollier And Nico Vandervelpen Resign From Board
7/5/2017 10:04:05 AM Diasome Pharma Receives Funding Led By Medicxi
6/22/2017 8:34:51 AM Minerva Reports Completion Of Bridging Study To Select Improved Formulation Of MIN-101 For Use In Phase 3 Trial
5/4/2017 8:11:57 AM Minerva Neurosciences Q1 Net Loss $10.6 Mln Or $0.30/shr Vs. Net Loss $8.0 Mln Or $0.29/shr Last Year
3/13/2017 7:46:40 AM Minerva Neurosciences Q4 Net Loss $9.4 Mln Or $0.27/shr Vs. Net Loss Of $8.4 Mln Or $0.34/shr Prior Year
12/20/2016 8:33:44 AM Minerva Neurosciences Names Michael Davidson As Chief Medical Officer
11/3/2016 7:51:48 AM Minerva Neurosciences Q3 Loss Per Share $0.24, Same As Last Year
10/26/2016 8:35:08 AM Minerva Reports Positive Data From Six-Month Extension Of Phase IIb Trial Of MIN-101 Monotherapy In Schizophrenia
10/6/2016 3:01:01 AM Kymo Therapeutics Formed By Metabrain Research And Medicxi; Kymo To Receive Up To €10 Mln From Medicxi
9/26/2016 8:34:06 AM Minerva Neurosciences Receives FDA Acceptance Of Investigational New Drug Application For MIN-117
8/4/2016 7:39:35 AM Minerva Neurosciences Q2 Loss Per Share $0.18 Vs Loss $0.27 Last Year